logo
COVID wave is moving across USA: Health experts warn parents that children must do this

COVID wave is moving across USA: Health experts warn parents that children must do this

Time of India3 days ago
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
FAQs
Tired of too many ads?
Remove Ads
United States of America is witnessing a late-summer COVID wave, even as children are preparing to return to school. Fortunately, hospitalization rates remain low. The risk of severe illness and hospitalization among children younger than 1 who are infected with the coronavirus is comparable to that among adults 65 and older. That's why experts have said that a child's first exposure should be through a vaccine, rather than infection. However, this fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID, as per a report.Public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the CDC, NYT News Service reported. Pfizer 's vaccine has long been available to these children under so-called emergency use authorization. But the Food and Drug Administration is considering discontinuing the authorization for that age group, according to an email sent by the Centers for Disease Control and Prevention to state and local health departments.Pfizer confirmed the possibility Monday evening and said that the company was "currently in discussions with the agency on potential paths forward." For children 5 to 11 years old, the Pfizer vaccine is expected to be approved and available, according to the CDC's email, which was reviewed by The New York Times.In July, the FDA granted full approval to Moderna's COVID vaccine for children -- but only for those who have health conditions that may put them at increased risk should they become infected. Novavax's COVID vaccine has never been available for children younger than 12.The upshot is that if the FDA does not renew Pfizer's authorization for children 6 months to 4 years, or fully approve the vaccine, healthy children in that age group will have no officially sanctioned options -- although doctors may still choose to provide the vaccine "off label."In May, Health Security Robert F. Kennedy Jr. announced that COVID vaccines would no longer be offered to healthy children or pregnant women. Kennedy has called the Pfizer and Moderna vaccines dangerous. In May 2021, in the thick of the pandemic, he filed a petition with the FDA demanding that the agency revoke authorization for the shots.The CDC, which typically makes such recommendations, later walked back the secretary's statement, saying that healthy children could get the shot if a doctor agreed that it was needed.Moderna told the CDC it was ramping up supplies of its vaccine for the fall, according to the agency's email. But it is not approved for healthy children, and if the FDA rescinds authorization for children younger than 5, parents of healthy children will find themselves with no options.Andrew Nixon, a spokesperson for the Department of Health and Human Services, declined to comment on potential regulatory changes and said any reports before an official statement should be treated as "speculation."But public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the CDC.The vaccines have also been shown to offer modest protection against long COVID in some children. The effects are already becoming apparent. Providers have stopped ordering last year's shot, as they often do at this time of the year. Normally by this point, there would be a clear plan for the 2025-26 season.A1. The full form of CDC is Centers for Disease Control and Prevention.A2. Full form of FDA is Food and Drug Administration.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anti-rabies vaccine, immunoglobulin sales pick up as dog bite cases jump
Anti-rabies vaccine, immunoglobulin sales pick up as dog bite cases jump

Business Standard

time2 hours ago

  • Business Standard

Anti-rabies vaccine, immunoglobulin sales pick up as dog bite cases jump

Sanket Koul New Delhi Listen to This Article Anti-rabies vaccine (ARV) and immunoglobulin sales are gradually recovering after the Covid-19 slump, amid a marked increase in dog bite incidence. The rise in sales follows a 76 per cent increase in dog bites, from 2.1 million in 2022 to 3.7 million in 2024. As a result, vaccine makers are preparing to ratchet up production. Bharat Serums and Vaccines (BSV), an arm of Mankind Pharma, told Business Standard that it aims to expand manufacturing by 15-20 per cent, supporting India's mission to eliminate rabies through timely and complete after-exposure treatment. Data from market research firm Pharmarack shows that the combined

PM Modi asks scientists to focus on R&D, secure patents for new drugs
PM Modi asks scientists to focus on R&D, secure patents for new drugs

Business Standard

time5 hours ago

  • Business Standard

PM Modi asks scientists to focus on R&D, secure patents for new drugs

Prime Minister Narendra Modi on Friday asked scientists and entrepreneurs to focus more on research and development (R&D) and secure patents for new drugs and medical technologies to ensure self-reliance in the pharmaceutical segment. Speaking from the Red Fort on the occasion of India's 79th Independence Day, PM Modi said that this move will ensure that India not only meets its own healthcare needs but also becomes a global hub of medical innovation. The call comes at a time when India has been lagging behind in terms of R&D spending, according to a Department of Pharmaceuticals (DoP) study paper on industry-academia linkages in the segment. It states that while a number of initiatives for industry-academic linkages in India have produced positive research results over the years, due to their sporadic nature, India's share of world researchers has remained at about 2 per cent, compared to 20 per cent in the US and China. 'An analysis of the share in R&D reveals that in India, the government contributes between 75 and 80 per cent, the private sector contributes 20 to 25 per cent, and universities contribute 3 per cent,' the paper added. In comparison, OECD countries see a 69 per cent contribution from private sector companies, followed by universities at 18 per cent, government contribution at 10 per cent, and non-profit organisations at 3 per cent. Commenting on the issues faced by the pharma industry, Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, told CNBC TV18 that the timeline to take a new molecule from the lab to the market is a very long process, making investments in research and innovation very risky. 'Unless we have very bold regulatory reforms that shorten this lab-to-market journey, we may not see the research investment needed for a country like India,' she added. Calling on the industry to demonstrate India's ability to lead in science, technology, and human welfare, PM Modi also urged the nation to achieve self-reliance in medicines and innovation, highlighting the country's strength as the pharmacy of the world. India currently has approximately 3,000 pharmaceutical businesses with over 10,500 manufacturing facilities, offering around 60,000 generic brands in 60 therapeutic categories. Many Indian pharmaceutical companies are now looking to jump on the generic bandwagon for off-patent molecules, while pressing on plans to develop a biosimilars pipeline post the Covid-19 pandemic. Pharma firms have gone on a generic spree after several blockbuster molecules used in diabetes medications, such as empagliflozin and dapagliflozin, went off patent in the last two years. Major blockbuster molecules that have seen several generic launches in this timeframe include empagliflozin and dapagliflozin, used in diabetes medications, which saw the prices of these drugs fall by 85 per cent in the Indian market. Similarly, companies such as Sun Pharma, Torrent, Lupin, Glenmark, and Dr Reddy's are also working on generic versions of weight loss drugs based on the blockbuster molecule semaglutide, which is expected to go off patent by March 2026. According to the DoP's study paper, more than 300 drug patents in different categories and geographies will be expiring every year during the patent cliff period of 2022 to 2032. 'The patent cliff will provide an opportunity for Indian generic companies to enter the US and other regulated markets and produce more affordable versions of those medications,' the paper added. PM flags obesity crisis in I-Day speech, calls for less oil intake PM Modi on Friday expressed concerns over obesity becoming a future crisis for India, asking people to cut down consumption of cooking oil by at least 10 per cent. India is currently projected to have the third-highest population of overweight or obese people globally, after the United States of America (USA) and China. Asking every family to take the concern seriously, the Prime Minister resolved that the country must protect itself from obesity. 'While many steps will have to be taken, I have made one small suggestion that every family should resolve that when cooking oil comes into the house, it should be 10 per cent less than usual, and its use should also be 10 per cent less. By doing so, we shall make our contribution towards winning the fight against obesity,' he stated from the ramparts of the Red Fort. According to the National Family Health Survey-5 (2019-21), 24 per cent of women and 23 per cent of men in India are overweight or obese, a sharp rise from 20.7 per cent and 18.6 per cent recorded in the NFHS-4 (2015-16), respectively. A recent Lancet study had also predicted that nearly one-third of the country's population, amounting to 218 million men and 231 million women, will be obese by 2050.

Fourth person dies amid Legionnaires' outbreak in NYC: Here are key symptoms
Fourth person dies amid Legionnaires' outbreak in NYC: Here are key symptoms

Hindustan Times

time7 hours ago

  • Hindustan Times

Fourth person dies amid Legionnaires' outbreak in NYC: Here are key symptoms

A fourth person has died amid a Legionnaires' disease outbreak in New York City, officials said Thursday, per AP. They also confirmed that some cooling towers that tested positive for the bacteria are located in city-run buildings. Legionnaires' disease is a form of pneumonia caused by bacteria that grow in warm water and spread through water systems in buildings. (Representative image)(Pexel) The outbreak began in late July in Central Harlem and has infected dozens. As of Thursday, 17 people had been hospitalized, according to the health department. The Legionella bacteria, which causes the disease, was found in 12 cooling towers on 10 buildings. These included a city-run hospital and a sexual health clinic. Officials said 11 of the towers have been cleaned, and the last one is scheduled for cleaning by Friday. Legionnaires' disease is a form of pneumonia caused by bacteria that grow in warm water and spread through water systems in buildings. In this outbreak, the bacteria were traced to cooling towers that use water and fans to cool air. Legionnaires' disease symptoms According to the CDC, symptoms include cough, fever, headache, muscle pain, and shortness of breath, usually appearing two to 14 days after exposure. Dr. Michelle Morse, the city's acting health commissioner, said new cases in Central Harlem are declining, which shows that the sources have been contained. She advised anyone in the area with flu-like symptoms to contact a doctor. For the first time, officials released the names of buildings linked to the outbreak. Mayor Eric Adams confirmed Harlem Hospital is among them. Cooling towers are at these locations: BRP Companies, Lafayette Development LLC, 2239 Adam Clayton Powell Jr Blvd BVK, 215 West 125th Street Commonwealth Local Development, 301 West 124th Street CUNY City College Marshak Science Building, 181 Convent Avenue Harlem Center Condo, 317 Lenox Avenue NYC Economic Development Corporation, 40 West 137th Street NYC Health Department Central Harlem Sexual Health Clinic, 2238 Fifth Avenue NYC Health + Hospitals Harlem Hospital, 506 Lenox Avenue NY Hotel Trades Council Harlem Health Center, 133 Morningside Avenue Wharton Properties, 100 West 125th Street (3 of 8 towers) Officials said the cooling towers are separate from building plumbing, so the water supply is not impacted, according to an ABC7 news report. 'Residents can continue to drink water, bathe, shower, cook and use their air conditioner,' the city officials said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store